Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
95 studies found for:    Open Studies | "Cholangiocarcinoma"
Show Display Options
Rank Status Study
21 Recruiting TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Procedure: TACE+Tegafur;   Procedure: TACE
22 Not yet recruiting SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin-gemcitabine;   Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
23 Recruiting A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: LDK378
24 Recruiting Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Condition: Hilar Cholangiocarcinoma
Interventions: Drug: Photodynamic therapy-Photofrin;   Procedure: Stenting procedure;   Drug: Chemotherapy regimen
25 Recruiting Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Device: LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo;   Drug: Gem-Cis or Gem-Carbo
26 Recruiting Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Condition: Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Intervention: Drug: H3B-6527
27 Recruiting Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Conditions: Intrahepatic Cholangiocarcinoma;   Mixed Hepatocellular Cholangiocarcinoma;   Cholangiocarcinoma
Intervention:
28 Recruiting Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Liver Neoplasms
Interventions: Drug: Floxuridine;   Drug: Dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin
29 Recruiting Treatment for Bile Duct Cancer in the Liver
Condition: Cholangio Carcinoma
Intervention: Drug: SIRT Yttrium-90
30 Recruiting Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct;   Gallbladder Cancer
Interventions: Procedure: biological test;   Drug: GEMOX;   Drug: Cetuximab;   Drug: Trastuzumab;   Drug: Gefitinib;   Drug: Lapatinib;   Drug: Everolimus;   Drug: Sorafenib;   Drug: Crizotinib
31 Recruiting Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Conditions: Hepatocellular Carcinoma;   Intrahepatic Cholangiocarcinoma
Interventions: Device: Delcath Hepatic Delivery System;   Drug: Melphalan
32 Recruiting Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Conditions: Intrahepatic Cholangiocarcinoma;   Peripheral Cholangiocarcinoma;   Cholangiolar Carcinoma;   Cholangiocellular Carcinoma
Interventions: Drug: Floxuridine (FUDR);   Drug: dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Other: MRI;   Other: Research blood draws
33 Recruiting The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells
Condition: Cholangiocarcinoma
Intervention: Drug: cytokine induced killer cells
34 Recruiting RFA RCT for Pancreatic or Bile Duct Cancer
Conditions: Unresectable Pancreatic Cancer;   Cholangiocarcinoma Non-resectable
Interventions: Procedure: Radiofrequency Ablation using EndoHPB Probe;   Procedure: Stenting only
35 Recruiting Endobiliary RFA for Unresectable Malignant Biliary Strictures
Conditions: Cholangiocarcinoma;   Ampullary Carcinoma
Intervention: Procedure: Radiofrequency ablation (RFA)
36 Recruiting Photodynamic Therapy (PDT) Cholangiocarcinoma Registry
Conditions: Unresectable Cholangiocarcinoma;   Biliary Obstruction;   Stent Obstruction;   Biliary Stricture
Intervention: Procedure: Photodynamic Therapy
37 Recruiting Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Biliary Stricture;   Biliary Obstruction;   Bile Duct Cancer
Intervention: Procedure: Photodynamic Therapy
38 Recruiting Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer
Conditions: Cholangiocarcinoma;   Gall Bladder Carcinoma
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Other: Observation
39 Recruiting A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Condition: Metastatic Biliary Tract Carcinoma
Intervention: Drug: Regorafenib
40 Recruiting Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study
Condition: Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
Interventions: Device: Radiofrequency ablation with stenting;   Device: stenting

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.